Enhancing Photodynamic Therapy with COX-2 Inhibition

通过 COX-2 抑制增强光动力疗法

• 批准号: 6689681
• 负责人: CHARLES Joseph GOMER
• 金额: $ 33.11万
• 依托单位: CHILDREN'S HOSPITAL OF LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6689681
• 关键词: angiogenesis; apoptosis; combination chemotherapy; enzyme activity; gel mobility shift assay; gene expression; gene targeting; genetic transcription; genetically modified animals; immunocytochemistry; laboratory mouse; neoplasm /cancer pharmacology; neoplasm /cancer photoradiation therapy; neoplastic growth; nonhuman therapy evaluation; nonsteroidal antiinflammatory agent; oxidoreductase inhibitor; photosensitizing agents; prostaglandin endoperoxide synthase; protein binding; terminal nick end labeling; transfection /expression vector

DESCRIPTION (provided by applicant): The long-term objective of our proposal is to improve the efficacy of photodynamic therapy (PDT) for the treatment of solid tumors. PDT continues to be useful for the clinical treatment of a variety of malignancies. However, the procedure has not been optimized and tumor recurrences can occur. The rationale for this application builds upon recent preliminary data suggesting that a combined modality approach using a cyclooxygenase-2 (COX-2) inhibitor may improve PDT effectiveness. COX-2 is a rate-limiting enzyme in the biosynthesis of prostanoids and it is expressed in many tumors. Studies indicate that COX-2 expression is correlated with tumor survival, proliferation, and/or angiogenesis. Positive COX-2 expression in tumors has also been associated with poor clinical prognosis. These observations have led scientists to evaluate the role that COX-2 specific inhibitors can play in the prevention and treatment of tumors. We initially examined gene expression profiles following PDT in murine tumor cells and observed a 25 fold increase in COX-2 mRNA. We subsequently observed that biologically active COX-2 protein was significantly elevated above basal levels in tumors treated with non-curative PDT doses. This suggests tumor cells that escape eradication following PDT treatment may exhibit a pro-survival phenotype associated with COX-2 overexpression. Our pilot study also shows that adjunctive administration of a COX-2 selective inhibitor improves PDT mediated tumor killing, which further suggests that COX-2 expression may be an important determinant in PDT efficacy. We hypothesize that PDT mediated expression of COX-2 decreases treatment efficacy and that combining PDT with a COX-2 selective inhibitor will improve the therapeutic responsiveness of PDT. In order to better understand and optimize this novel combined modality approach we propose three specific aims: (1) to determine molecular mechanisms regulating PDT mediated COX-2 expression, (2) to determine how COX-2 inhibition improves PDT tumor response, and (3) to optimize procedures for enhancing PDT efficacy using a COX-2 selective inhibitor. If our preliminary findings are confirmed by studies outlined in this proposal, adjunctive COX-2 inhibitor treatment could provide a safe and effective method for improving clinical PDT.

描述（由申请人提供）：我们提案的长期目标是提高光动力疗法（PDT）对实体瘤治疗的疗效。 PDT仍然可用于对各种恶性肿瘤的临床治疗。但是，该过程尚未优化，并且可能会发生肿瘤复发。该应用程序的基本原理是基于最近的初步数据，表明使用环氧酶-2（COX-2）抑制剂的组合方式方法可以提高PDT效率。 COX-2是前列腺素生物合成中的限速酶，在许多肿瘤中都表达。研究表明，COX-2表达与肿瘤存活，增殖和/或血管生成相关。肿瘤中的COX-2阳性表达也与临床预后不良有关。这些观察结果使科学家评估了COX-2特异性抑制剂在预防和治疗肿瘤中的作用。我们最初检查了鼠肿瘤细胞中PDT之后的基因表达谱，并观察到COX-2 mRNA增加了25倍。随后，我们观察到，在用非耐抑制性PDT剂量治疗的肿瘤中，生物活性的COX-2蛋白显着升高。这表明PDT治疗后逃避根除的肿瘤细胞可能表现出与COX-2过表达相关的生存表型。我们的试点研究还表明，辅助施用COX-2选择性抑制剂可改善PDT介导的肿瘤杀伤，这进一步表明COX-2表达可能是PDT功效的重要决定因素。我们假设PDT介导的COX-2表达降低了治疗疗效，并且将PDT与COX-2选择性抑制剂结合起来将提高PDT的治疗反应性。为了更好地理解和优化这种新型的组合方式方法，我们提出了三个具体目的：（1）确定调节PDT介导的COX-2表达的分子机制，（2）确定COX-2抑制如何改善PDT肿瘤反应，以及（3）以优化使用COX-2选择性抗抑制剂来增强PDT效率的程序。如果我们的初步发现通过该提案中概述的研究确认，则辅助COX-2抑制剂治疗可以为改善临床PDT提供安全有效的方法。